Literature DB >> 8345046

Pulsatile luteinizing hormone patterns in long term oral contraceptive users.

D J Hemrika1, E H Slaats, J C Kennedy, T J de Vries Robles-Korsen, J Schoemaker.   

Abstract

Oral contraceptives (OC) inhibit folliculogenesis by a central suppressive action on the release of gonadotropins. To characterize the nature of these central effects, we studied 40 long term OC users on 3 different OCs: two monophasic preparations with 30 micrograms ethinyl estradiol and 150 micrograms l-norgestrel (group 1; n = 15), 150 micrograms desogestrel (group 2; n = 10), and a triphasic formulation containing 30-40 micrograms ethinyl estradiol and 50, 75, and 125 micrograms l-norgestrel (group 3; n = 15). Blood sampling at 10-min intervals during 6-h periods was performed at different moments in the pill cycle. Thirteen healthy volunteers with regular ovulatory cycles served as normal controls. FSH and LH were measured by a sensitive immunoradiometric assay. Pulsatile LH release was observed in all OC users. Mean serum LH and FSH levels, number of LH pulses per 6 h, and the amplitude of LH pulses on day 1 of the pill cycle did not differ from early follicular phase control values. FSH levels were rapidly suppressed from day 2 onward in all three groups, whereas LH levels progressively declined in groups 1 and 2 from day 8 onward. In group 3, however, LH levels were only significantly suppressed after day 13. The number of LH pulses per 6 h decreased in all groups starting on day 2, whereas the amplitude of LH pulses increased. A substantial percentage of LH pulses observed in OC users after day 1 were of low amplitude (< 0.75 IU/L). From these results, we conclude that 1) pulsatile release of LH is maintained during OC use; 2) FSH levels are suppressed equally early and equally effective by all OCs studied; 3) during OC use, the number of LH pulses per 6 h is reduced; 4) modulation of LH pulse amplitudes, and subsequently of serum LH levels, is mainly mediated by a dose- and time-dependent effect of the gestagenic component of the OC; and 5) after the 7-day pill-free interval, a normal early follicular phase pulse pattern is found, even in long term OC users, suggesting that in this period, most of the steroidogenic feedback effects wear off.

Entities:  

Keywords:  Biology; Clinical Research; Contraception; Contraceptive Methods; Endocrine System; Examinations And Diagnoses; Family Planning; Follicle Stimulating Hormone--analysis; Gonadotropins; Gonadotropins, Pituitary; Hormones; Laboratory Examinations And Diagnoses; Laboratory Procedures; Luteinizing Hormone--analysis; Oral Contraceptives; Oral Contraceptives, Low-dose; Physiology; Research Methodology

Mesh:

Substances:

Year:  1993        PMID: 8345046     DOI: 10.1210/jcem.77.2.8345046

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  9 in total

1.  The addition of norethindrone acetate to leuprolide acetate for ovarian suppression has no adverse effect on ovarian stimulation.

Authors:  E C Ditkoff; R Prosser; R C Zimmermann; S Lindheim; M V Sauer
Journal:  J Assist Reprod Genet       Date:  1997-02       Impact factor: 3.412

2.  Oral contraceptives and sexuality in university women.

Authors:  N L McCoy; J R Matyas
Journal:  Arch Sex Behav       Date:  1996-02

Review 3.  Evidence that obesity and androgens have independent and opposing effects on gonadotropin production from puberty to maturity.

Authors:  Robert L Rosenfield; Brian Bordini
Journal:  Brain Res       Date:  2010-09-25       Impact factor: 3.252

Review 4.  Gonadotrophin-releasing hormone nerve terminals, tanycytes and neurohaemal junction remodelling in the adult median eminence: functional consequences for reproduction and dynamic role of vascular endothelial cells.

Authors:  V Prevot; N Bellefontaine; M Baroncini; A Sharif; N K Hanchate; J Parkash; C Campagne; S de Seranno
Journal:  J Neuroendocrinol       Date:  2010-05-18       Impact factor: 3.627

5.  Close examination of steroidogenesis disorders in a DOC- and progesterone-producing adrenocortical carcinoma.

Authors:  Masakatsu Sone; Hirotaka Shibata; Keiko Homma; Naohisa Tamura; Jun-Ichi Akahira; Satoshi Hamada; Mitsuhiko Yahata; Nobuyuki Fukui; Hiroshi Itoh; Hironobu Sasano; Kazuwa Nakao
Journal:  Endocrine       Date:  2008-11-05       Impact factor: 3.633

6.  Reproductive factors, hormone use and gastric cancer risk: The Singapore Chinese Health Study.

Authors:  Zhensheng Wang; Lesley M Butler; Anna H Wu; Woon-Puay Koh; Aizhen Jin; Renwei Wang; Jian-Min Yuan
Journal:  Int J Cancer       Date:  2016-03-10       Impact factor: 7.396

7.  Pharmacokinetics and Pharmacodynamics of Follicle-Stimulating Hormone in Healthy Women Receiving Single and Multiple Doses of Highly Purified Human Menotrophin and Urofollitrophin.

Authors:  Andrea F D Di Stefano; Antonio Rusca; Milko M Radicioni; Luca Loprete; Daniela Binelli; Giorgio Caccia; Barbara Cometti
Journal:  Clin Drug Investig       Date:  2016-12       Impact factor: 2.859

8.  An Update on Contraception in Polycystic Ovary Syndrome.

Authors:  Seda Hanife Oguz; Bulent Okan Yildiz
Journal:  Endocrinol Metab (Seoul)       Date:  2021-04-15

9.  A Year Through the COVID-19 Pandemic: Deleterious Impact of Hormonal Contraception on Psychological Distress in Women.

Authors:  Alexandra Brouillard; Lisa Marie Davignon; Justine Fortin; Marie France Marin
Journal:  Front Psychiatry       Date:  2022-03-16       Impact factor: 4.157

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.